Xemb0dxvb43zzsf2lcidm5z3
Xemb0dxvb43zzsf2lcidm5z3
Xemb0dxvb43zzsf2lcidm5z3
Test Report
*470149702* Page 1 of 12
.
Test Report
*470149702* Page 2 of 12
.
Test Report
Note
1. Measurements in the same patient can show physiological & analytical variations. Three serial
samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
2. Additional testing for Apolipoprotein B, hsCRP, Lp(a ) & LP-PLA2 should be considered
among patients with moderate risk for ASCVD for risk refinement.
*470149702* Page 3 of 12
.
Test Report
Notes
1. Interpretation of the result should be considered in relation to clinical circumstances.
2. It is recommended to consider supplementary testing with plasma Methylmalonic acid (MMA) or
plasma homocysteine levels to determine biochemical cobalamin deficiency in presence of clinical
suspicion of deficiency but indeterminate levels. Homocysteine levels are more sensitive but MMA is
more specific
3. False increase in Vitamin B12 levels may be observed in patients with intrinsic factor blocking
antibodies, MMA measurement should be considered in such patients
4. The concentration of Vitamin B12 obtained with different assay methods cannot be used
interchangeably due to differences in assay methods and reagent specificity
Interpretation
--------------------------------------------------------------------------------------------
| LEVEL | REFERENCE RANGE IN nmol/L| COMMENTS |
|---------------|--------------------------|-------------------------------------------------|
| Deficient | < 50 | High risk for developing bone disease |
|---------------|--------------------------|-------------------------------------------------|
| Insufficient | 50-74 | Vitamin D concentration which normalizes |
| | | Parathyroid hormone concentration |
|---------------|--------------------------|-------------------------------------------------|
| Sufficient | 75-250 | Optimal concentration for maximal health benefit|
|---------------|--------------------------|-------------------------------------------------|
| Potential | >250 | High risk for toxic effects |
| intoxication | | |
--------------------------------------------------------------------------------------------
*470149702* Page 4 of 12
.
Test Report
Note
1. TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a
minimum between 6-10 pm . The variation is of the order of 50% . hence time of the day has
influence on the measured serum TSH concentrations.
2. Alteration in concentration of Thyroid hormone binding protein can profoundly affect Total T3 and/or
Total T4 levels especially in pregnancy and in patients on steroid therapy.
3. Unbound fraction ( Free,T4 /Free,T3) of thyroid hormone is biologically active form and correlate
more closely with clinical status of the patient than total T4/T3 concentration
4. Values <0.03 uIU/mL need to be clinically correlated due to presence of a rare TSH variant in
some individuals
AMYLASE, SERUM
(G7PNP)
*470149702* Page 5 of 12
.
Test Report
*470149702* Page 6 of 12
.
Test Report
Interpretation
HbA1c result is suggestive of at risk for Diabetes (Prediabetes)/ well controlled Diabetes in a known Diabetic
Interpretation as per American Diabetes Association (ADA) Guidelines
------------------------------------------------------------------------------------------
| Reference Group | Non diabetic | At risk | Diagnosing | Therapeutic goals |
| | adults >=18 years | (Prediabetes) | Diabetes | for glycemic control |
| ----------------|-------------------|---------------|-------------|----------------------|
| HbA1c in % | 4.0-5.6 | 5.7-6.4 | >= 6.5 | <7.0 |
------------------------------------------------------------------------------------------
Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered,
particularly when the HbA1C result does not correlate with the patient’s blood glucose levels.
---------------------------------------------------------------------------------
| FACTORS THAT INTERFERE WITH HbA1C | FACTORS THAT AFFECT INTERPRETATION |
| MEASUREMENT | OF HBA1C RESULTS |
|--------------------------------------|------------------------------------------|
| Hemoglobin variants,elevated fetal | Any condition that shortens erythrocyte |
| hemoglobin (HbF) and chemically | survival or decreases mean erythrocyte |
| modified derivatives of hemoglobin | age (e.g.,recovery from acute blood loss,|
| (e.g. carbamylated Hb in patients | hemolytic anemia, HbSS, HbCC, and HbSC) |
| with renal failure) can affect the | will falsely lower HbA1c test results |
| accuracy of HbA1c measurements | regardless of the assay method used.Iron |
| | deficiency anemia is associated with |
| | higher HbA1c |
---------------------------------------------------------------------------------
*470149702* Page 7 of 12
.
Test Report
Apolipoprotein B
-----------------------------------------------------------------------------
| RESULT IN mg/dL | REMARKS |
|--------------------------|-------------------------------------------------|
| <23 |Abetalipoproteinemia/Hypobetalipoproteinemia |
|--------------------------|-------------------------------------------------|
| 23-45 |Hypobetalipoproteinemia |
|--------------------------|-------------------------------------------------|
| 46-135 |Normal |
| -------------------------|-------------------------------------------------|
| >135 |Hyperapobetalipoproteinemia/Increased CAD risk |
--------------------------|-------------------------------------------------
Apo B to A1 Ratio
-------------------------------
| RATIO | REMARKS |
|------------|------------------|
| 0.35-0.98 | Desirable |
|------------|------------------|
| >0.98 |Increased CAD risk|
-------------------------------
*470149702* Page 8 of 12
.
Test Report
Physical
pH 5 5.0 - 8.0
Chemical
Microscopy
*470149702*
Page 9 of 12
.
Test Report
HEMOGRAM
*470149702* Page 10 of 12
.
Test Report
*470149702* Page 11 of 12
.
Test Report
*470149702* Page 12 of 12